New eczema drug shows promise in early trial
NCT ID NCT03822832
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested a drug called spesolimab (BI 655130) in 51 adults with moderate to severe atopic dermatitis (eczema). Participants received either the drug or a placebo intravenously. The study measured how much eczema severity changed over 16 weeks using the EASI score, and also tracked side effects. The goal was to see if the drug is safe and effective for treating this chronic skin condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Spesolimab (BI 655130)
- What this could lead to
- If successful, this could lead to a new treatment option for people with moderate to severe atopic dermatitis that is not well controlled by current therapies.
- What could go wrong
- This is an early Phase 2 trial with only 51 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects not yet seen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aichi Medical University Hospital
Aichi, Nagakute, 480-1195, Japan
-
Center for Clinical Studies
Webster, Texas, 77598, United States
-
Center for Dermatology and Plastic Surgery
Scottsdale, Arizona, 85260, United States
-
Clinical Physiology Associates
Fort Myers, Florida, 33912, United States
-
Dermatology Treatment and Research Center, PA
Dallas, Texas, 75230, United States
-
Finlay Medical Research Corp
Miami, Florida, 33126, United States
-
ForCare Clinical Research, Inc.
Tampa, Florida, 33613, United States
-
Hosui General Medical Clinic
Hokkaido, Sapporo, 064-0807, Japan
-
Innovaderm Research Inc.
Montreal, Quebec, H2X 2V1, Canada
-
Kurume University Hospital
Fukuoka, Kurume, 830-0011, Japan
-
Nagasaki University Hospital
Nagasaki, Nagasaki, 852-8501, Japan
-
National Hospital Organization Kyushu Medical Center
Fukuoka, Fukuoka, 810-8563, Japan
-
NewLab Clinical Research Inc.
St. John's, Newfoundland and Labrador, A1C 2H5, Canada
-
Osaka City University Hospital
Osaka, Osaka, 545- 8586, Japan
-
Progressive Clinical Research
San Antonio, Texas, 78213, United States
-
Showa University Hospital
Tokyo, Shinagawa-ku, 142-8666, Japan
-
Tennocho Ekimae Dermatology and Allergology
Kanagawa, Yokohama, 240-0004, Japan
-
The Indiana Clinical Trials Center, PC
Plainfield, Indiana, 46168, United States
-
Tokyo Medical University Hachioji Medical Center
Tokyo, Hachioji, 193-0998, Japan
-
Unity Clinical Research
Oklahoma City, Oklahoma, 73118, United States
-
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Kyoto, 602-8566, Japan
-
University of Alberta Hospital (University of Alberta)
Edmonton, Alberta, T6G 2B7, Canada
-
University of South Florida
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World dupixent: does it live up to the hype for eczema?
- Scientists hunt for biological clues to severe childhood eczema
- Can a drug calm severe eczema itch when the rash is mild? a new study investigates
- Eczema drug nemolizumab put to the vaccine test
- New eczema drug enters first human tests
- Eczema drug study pulled before it started